CVT-4325 inhibits myocardial fatty acid uptake and improves left ventricular systolic function without increasing myocardial oxygen consumption in dogs with chronic heart failure

Cardiovascular Drugs and Therapy

Volumn 21, Issue 1, 2007, Pages 9-15

  Imai, Makoto ^a   Rastogi, Sharad ^a   Sharma, Naveen ^b   Chandler, Margaret P ^b   Sharov, Victor G ^a   Blackburn, Brent ^c   Belardinelli, Luiz ^c   Stanley, William C ^b   Sabbah, Hani N ^a,d  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CV THERAPEUTICS INC   (United States)

^d HENRY FORD HOSPITAL   (United States)

Author keywords

Cardiac metabolism; Fatty acids; Glucose; Heart failure; Myocardial oxygen consumption

Indexed keywords

CVT 2540; CVT 4325; FATTY ACID; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL EMBOLISM; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOG; DRUG EFFECT; FATTY ACID TRANSPORT; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEMODYNAMIC MONITORING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOGS; FATTY ACIDS; HEART FAILURE; INJECTIONS, INTRAVENOUS; MYOCARDIUM; OXADIAZOLES; OXYGEN CONSUMPTION; PIPERAZINES; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT;

EID: 34247140266     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-006-0496-5     Document Type: Article

References (35)

1. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.
2. Ingwall JS, Weiss RG. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 2004;95:135-45.
3. Mjos OD. Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971;50:1386-9.
4. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol Heart Circ Physiol 2000;278:H1345-51.
5. Simonsen S, Kjekshus JK. The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation 1978;58:484-91.
6. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, Gropler RJ. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271-7.
7. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998;83:969-79.
8. Lei B, Lionetti V, Young ME, Chandler MP, d'Agostino C, Kang E, et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 2004;36:567-76.
9. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M, et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994;43:174-9.
10. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ, et al. J, Huang H et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol Heart Circ Physiol 2004; 287:H1538-43.
11. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8.
12. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004;25:634-41.
13. Lionetti V, Linke A, Chandler MP, Young ME, Penn MS, Gupte S, et al. Carnitine palmitoyl transferase-I inhibition prevents ventricular remodeling and delays decompensation in pacing-induced heart failure. Cardiovasc Res 2005;66:454-61.
14. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-21.
15. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164-70.
16. Rosano GM, Vitale C, Sposato B, Mrtcuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
17. Elzein E, Ibrahim P, Koltun DO, Rehder K, Shenk KD, Marquart TA, et al. CVT-4325: a potent fatty acid oxidation inhibitor with favorable oral bioavailability. Bioorg Med Chem Lett 2004;14:6017-21.
18. Fraser H, Ibrahim P, Blackburn BK, Belardinelli L. Conditional-dependent effects of CVT-4325, a novel fatty acid oxidation inhibitor, on palmitate utilization. J Am Coll Cardiol 2003;41(suppl 1):253A.
19. Sabbah HN, Stein PD, Kono T, Gheorghiade TB, Levine S, Jafri ET, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-84.
20. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
21. Chandler MP, Stanley WC, Morita H, Suzuki G, Roth BA, Blackburn B, et al. Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circ Res 2002;91:278-80.
22. Dodge HT, Sandler H, Baxley WA, Hawley RR. Usefulness and limitations of radiographic methods for determining left ventricular volume. Am J Cardiol 1966;18:10-24.
23. Nikolaidis LA, Hentosz T, Doverspike A, Huerbin R, Stolarski C, Shen YT, et al. Catecholamine stimulation is associated with impaired myocardial O(2) utilization in heart failure. Cardiovasc Res 2002;53:392-404.
24. Nikolaidis LA, Trumble D, Hentosz T, Doverspike A, Huerbin R, Mathier MA, et al. Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MvO2 cost of catecholamines in heart failure). Eur J Heart Fail 2004;6:409-19.
25. Stanley WC. Ranolazine: new approach for the treatment of stable angina pectoris. Expert Rev Cardiovasc Ther 2005;3:821-9.
26. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-24.
27. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001;104:2407-11.
28. Ekelund UE, Harrison RW, Shokek O, Thakkar RN, Tunin RS, Senzaki H, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 1999;85:437-45.
29. Nelson GS, Berger RD, Fetics BJ, Talbot M, Spinelli JC, Hare JM, et al. Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation 2000;102:3053-9.
30. Stanley WC, Chandler MP. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail Rev 2002;7:115-30.
31. Borst P, Loos JA, Christ EJ, Slater EC. Uncoupling activity of long-chain fatty acids. Biochem Biophys Acta 1962;62: 509-18.
32. Pressman BC, Lardy HA. Effects of surface active agents on the latent ATPase of mitochondria. Biochem Biophys Acta 1956;21:458-66.
33. Panchal AR, Stanley WC, Kerner J, Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 1998;4: 121-6.
34. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1992;24:1333-47.
35. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30: 1757-62.